Pregledni rad

Quadrivalent vaccine against human papillomaviruses (HPV)

M. Poljak
S. Židovec-Lepej

Sažetak

Human papillomaviruses (HPV) are remarkably heterogeneous group of DNA viruses that are causally involved in the etiology of different benign and malignant neoplastic lesions of the anogenital, oropharyngeal and cutaneous epithelium. The prevention of HPV infection can be achieved by the induction of genotype-specific neutralizing antibodies triggered by recombinant L1 viral-like particle (VLP) vaccines. VLP are attractive candidates for prophylactic vaccines as they are empty, non-infectious, DNA-free viral capsids morphologically indistinguishable from the native viruses. Phase I and II trials have shown that the VLP-based HPV vaccines are well tolerated, that they induce high titers of neutralizing antibodies (50–100 fold greater than during natural infection), and protect with a very high efficacy against a persistent HPV infection and HPV-related clinical disease. Until now only one HPV vaccine completed phase III trials. The vaccine produced by Merck Sharpe & Dohme (Gardasil®, Silgard®), is a quadrivalent vaccine with HPV-6, HPV-11, HPV-16, and HPV-18 VLPs. Until January 2007, the quadrivalent HPV vaccine has been approved in 52 countries (all under accelerated review schedules) including the US, all 25 European Union member countries, Mexico, Australia, Canada, New Zealand, Peru and Brasil. Additional applications are currently under review with regulatory agencies in more than 50 countries around the world. According to the published data, the vaccine has been associated with minimal adverse reactions, the most common of which being local reactions.

Ključne riječi

HPV; human papillomaviruses; vaccine

Hrčak ID:

12655

URI

https://hrcak.srce.hr/12655

Datum izdavanja:

1.12.2006.

Podaci na drugim jezicima: hrvatski

Posjeta: 2.758 *